(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.29%) $79.18
(-0.59%) $2.02
(0.10%) $2 312.00
(0.17%) $26.88
(0.10%) $963.60
(-0.02%) $0.932
(-0.06%) $10.99
(-0.01%) $0.798
(-0.02%) $91.11
4 days till quarter result
(amc 2024-05-07)
Expected move: +/- 9.03%
@ $2.70
Išleistas: 14 vas. 2024 @ 16:30
Grąža: 21.48%
Ankstesnis signalas: vas. 12 - 19:17
Ankstesnis signalas:
Grąža: -2.17 %
Live Chart Being Loaded With Signals
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 1.67M |
Vidutinė apimtis | 2.84M |
Rinkos kapitalizacija | 295.09M |
EPS | $0 ( 2024-03-05 ) |
Kita pelno data | ( $-0.0900 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -25.23 |
ATR14 | $0.00600 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jenkins Abigail L. | Sell | 0 | Common Stock |
2024-03-15 | Schobel Alexander Mark | Sell | 50 000 | Common Stock |
2024-03-09 | Barber Daniel | Sell | 37 938 | Common Stock |
2024-03-09 | Boyd Peter E. | Sell | 8 370 | Common Stock |
2024-03-09 | Braender Lori J | Sell | 10 530 | Common Stock |
INSIDER POWER |
---|
89.71 |
Last 98 transactions |
Buy: 6 495 786 | Sell: 225 172 |
Tūris Koreliacija
Aquestive Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ATRS | 0.946 |
MDLZ | 0.94 |
MMSI | 0.939 |
CWST | 0.938 |
ISEE | 0.938 |
XLRN | 0.937 |
HAPP | 0.935 |
MTRY | 0.93 |
CFIV | 0.928 |
OSIS | 0.928 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
OBT | -0.951 |
HONE | -0.948 |
GBNY | -0.946 |
FRAF | -0.943 |
PFC | -0.943 |
WNEB | -0.942 |
AUB | -0.941 |
COFS | -0.941 |
EVBG | -0.94 |
PNBK | -0.934 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Aquestive Therapeutics Koreliacija - Valiuta/Žaliavos
Aquestive Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $50.58M |
Bruto pelnas: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2023 |
Pajamos: | $50.58M |
Bruto pelnas: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2022 |
Pajamos: | $47.68M |
Bruto pelnas: | $28.29M (59.34 %) |
EPS: | $-1.240 |
FY | 2021 |
Pajamos: | $50.83M |
Bruto pelnas: | $50.83M (100.00 %) |
EPS: | $-2.10 |
Financial Reports:
No articles found.
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.